Microscopic disease at second-look laparotomy in advanced ovarian cancer. 1985

L J Copeland, and D M Gershenson, and J T Wharton, and E N Atkinson, and N Sneige, and C L Edwards, and F N Rutledge

During the 11-year interval from January 1971 to January 1982, 50 of 246 patients with advanced (Stage III and IV) epithelial ovarian carcinoma at second-look laparotomy had biopsy or cytologic evidence of persistent microscopic carcinoma. The stage and grade profile include 46 Stage III and 4 Stage IV patients: 4 borderline, 9 grade 1, 20 grade 2 and 17 grade 3 patients. Following second-look laparotomy, 4 patients received no further therapy, 45 received chemotherapy, and 1 received external radiation. No patient was lost to follow-up, and the median interval off therapy was 24 months. Progressive or recurrent disease has manifest in 12 (24%). No recurrences have developed either in patients younger than age 40 or in patients with grade 1 tumors. Two patients died of leukemia, 1 died of heart disease, and 35 (70%) are alive with no evidence of disease. In patients developing recurrence, the median progression-free interval was 17.5 months, with a range of 6 to 46 months. The median interval of survival following disease progression was 7 months. There was no evidence of progression at 2 years and 5 years in 81% and 70% of patients, respectively. The uncorrected 2- and 5-year survival rates were 96% and 71%, respectively. The 5-year survival rates for grades 1, 2, and 3 were 100%, 79%, and 36%, respectively. Other variables analyzed include number of positive foci, residual tumor volume at initial surgery, cytologic findings at second-look laparotomy, type of chemotherapy, and number of courses of chemotherapy before second-look laparotomy. In summary, patients with only microscopic evidence of disease at second-look surgery have a good probability for extended survival.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012086 Reoperation A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery. Revision, Joint,Revision, Surgical,Surgery, Repeat,Surgical Revision,Repeat Surgery,Revision Surgery,Joint Revision,Revision Surgeries,Surgery, Revision
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

L J Copeland, and D M Gershenson, and J T Wharton, and E N Atkinson, and N Sneige, and C L Edwards, and F N Rutledge
April 1990, The New England journal of medicine,
L J Copeland, and D M Gershenson, and J T Wharton, and E N Atkinson, and N Sneige, and C L Edwards, and F N Rutledge
December 1982, Gynecologic oncology,
L J Copeland, and D M Gershenson, and J T Wharton, and E N Atkinson, and N Sneige, and C L Edwards, and F N Rutledge
December 1994, Gynecologic oncology,
L J Copeland, and D M Gershenson, and J T Wharton, and E N Atkinson, and N Sneige, and C L Edwards, and F N Rutledge
January 1987, Harefuah,
L J Copeland, and D M Gershenson, and J T Wharton, and E N Atkinson, and N Sneige, and C L Edwards, and F N Rutledge
May 2001, Acta obstetricia et gynecologica Scandinavica,
L J Copeland, and D M Gershenson, and J T Wharton, and E N Atkinson, and N Sneige, and C L Edwards, and F N Rutledge
February 1981, Gynecologic oncology,
L J Copeland, and D M Gershenson, and J T Wharton, and E N Atkinson, and N Sneige, and C L Edwards, and F N Rutledge
November 1994, Journal of surgical oncology,
L J Copeland, and D M Gershenson, and J T Wharton, and E N Atkinson, and N Sneige, and C L Edwards, and F N Rutledge
January 1997, European journal of gynaecological oncology,
L J Copeland, and D M Gershenson, and J T Wharton, and E N Atkinson, and N Sneige, and C L Edwards, and F N Rutledge
March 1994, Obstetrics and gynecology clinics of North America,
L J Copeland, and D M Gershenson, and J T Wharton, and E N Atkinson, and N Sneige, and C L Edwards, and F N Rutledge
February 1992, American journal of clinical oncology,
Copied contents to your clipboard!